SEC Form 4 · accession 0001179110-17-011306
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Albers
Officer — CEO and President · Director
Period of report
Aug 7, 2017
Accepted (ET)
Aug 9, 2017 · 6:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 7, 2017 | S | 17,214 | $49.21 | D | 18,272 | D | |
| Common StockF3 | Aug 7, 2017 | S | 2,786 | $48.29 | D | 15,486 | D | |
| Common StockF4 | Aug 8, 2017 | S | 10,000 | $50.70 | D | 5,486 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.89 to $49.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.51 per share.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.41 to $51.07 per share.